Nabsys Appoints Anthony Shuber as Chief Scientific Officer

Accomplished molecular biologist to guide company towards cancer genomics development

PROVIDENCE, R.I.--(BUSINESS WIRE)--Nabsys, Inc., a life sciences company pioneering semiconductor-based tools for genomic analysis, announced today that Anthony Shuber has joined the company as Vice President and Chief Scientific Officer. In this role, Shuber will lead the company's efforts in product strategy as the company transitions its initial commercial focus toward oncology.

"We are developing a platform that will not only enable researchers to study human health and disease, but will scale directly to clinical applications."
Shuber, an industry veteran and accomplished inventor, has over 24 years of experience in developing commercial diagnostics and research and applied genomics products and holds 50 patents. The announcement comes just weeks after the company announced it has appointed Steve Lombardi as President and Chief Executive Officer. In his CEO role, Lombardi is driving the commercialization of the Nabsys technology.

"The Nabsys technology enables analysis of large-scale structural variations in the human genome which are the hallmarks of diseases such as cancer," said Shuber. "We are developing a platform that will not only enable researchers to study human health and disease, but will scale directly to clinical applications."

Shuber joins Nabsys from Ignyta, Inc., an oncology precision medicine biotechnology company, where he served as Chief Technology Officer and Vice President. Prior to joining Ignyta, Shuber was Co-Founder and Chief Technology Officer of Predictive Biosciences, Inc., as well as scientific Co-Founder of Exact Sciences, where he led both companies' general scientific and applied research efforts. He also has experience at Genzyme Genetics / Integrated Genetics and Genetics Institute. Shuber was awarded the Colorectal Cancer Network's first annual 90 in 9 Science Award and holds a B.S. and M.S. degree in Biology from Marquette University.

"Tony brings over two decades of expertise in applied genomics and molecular diagnostics and has successfully developed and commercialized products to enable both researchers and physicians to better understand and diagnose cancer," said Lombardi. "As we continue to evolve the Nabsys platform and its commercial strategy, it is critical we add depth to the executive team in the area of human genomics. I am confident that Tony's scientific and clinical experience will prove to be invaluable as Nabsys begins to define its presence in the oncology marketplace."

Nabsys is dedicated to enabling advances in life sciences and healthcare through strategic deployment of its novel, patented platform that has broad applicability in DNA analysis. The semiconductor-based platform is capable of generating extremely long read lengths with unprecedented speed, accuracy, throughput and scalability.

About Nabsys

Nabsys is a private, venture-backed company based in Providence, RI. Its mission is to be the leading next generation DNA sequencing platform. The Nabsys platform enables high-throughput, low-cost detection of long read lengths of DNA. When combined with short-read sequencing, Nabsys data allows scientists to better answer questions of genome structure and function. The core of the Nabsys platform is a semiconductor-based device that electronically detects individual DNA fragments. An instrument automates the processing of multiple devices for high-throughput and ease of use. Nabsys was the first company to receive a "$1000 Genome" award from the National Human Genome Research Institute of the National Institutes of Health for an electronic approach to sequencing DNA. For more information about Nabsys, please visit www.Nabsys.com, and follow us on LinkedIn and Twitter.

Contacts

Media Contact:
Nabsys
Mary Alfieri, 617-624-3200
[email protected]

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.